Clinical Trials

17 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT06661720 2026-04-07

STRIKE

Phase 3 Recruiting

1,040 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

30 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Renal Cell

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07460206 2026-03-10

PRELUDE

Phase 2 Not yet recruiting

108 enrolled

Carcinoma, Renal Cell

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

75 enrolled

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

157 enrolled 26 charts

CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

10 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT05363631 2025-12-10

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

55 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03260504 2025-12-08

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 1 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

Carcinoma, Renal Cell

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

CNSDermatologicGenitourinary

18 enrolled

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06005818 2025-10-21

MRD GATE RCC

100 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07037004 2025-09-23

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

62 enrolled

Carcinoma, Renal Cell

NCT06302569 2025-09-09

REPRINT

23 enrolled

Carcinoma, Renal Cell

NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Phase 1/2 Withdrawn

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase 2 Withdrawn

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1 Completed

41 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT04267120 2025-03-21

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

11 enrolled 16 charts

Carcinoma, Renal Cell

NCT03149822 2025-03-13

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Phase 1/2 Completed

45 enrolled 17 charts

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04393350 2025-02-26

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

1,250 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02619253 2024-11-18

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma

Phase 1 Completed

52 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Renal Cell

NCT05485896 2024-09-19

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Phase 2 Completed

23 enrolled

Carcinoma, Renal Cell

NCT05024318 2024-05-16

NAPSTER

20 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Renal Cell

NCT03511391 2024-01-23

CHEERS

Phase 2 Completed

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT04187872 2023-12-27

TORCH

Phase 1 Terminated

10 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Phase 1 Completed

14 enrolled 13 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT06146777 2023-11-29

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Phase 3 Not yet recruiting

468 enrolled

Carcinoma, Renal Cell

NCT02855203 2023-08-03

RAPPORT

Phase 1/2 Completed

30 enrolled 11 charts

Carcinoma, Renal Cell

NCT03280667 2023-03-29

KEYPAD

Phase 2 Unknown

59 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

160 enrolled

Carcinoma, Renal Cell, Melanoma

NCT02348008 2022-09-14

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Phase 1/2 Completed

61 enrolled 17 charts

Carcinoma, Renal Cell

NCT04262427 2022-08-23

CAPER

Phase 1/2 Unknown

21 enrolled

Carcinoma, Renal Cell

NCT05263609 2022-08-02

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT03050060 2022-06-22

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

DermatologicGenitourinaryThoracic

21 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03115801 2021-09-22

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

6 enrolled 12 charts

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT02599779 2021-09-01

OZM-065

Phase 2 Completed

4 enrolled

Carcinoma, Renal Cell

NCT04995016 2021-08-06

PANDORA

Phase 2 Unknown

18 enrolled

Carcinoma, Renal Cell

NCT03189186 2021-04-05

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

Phase 1 Withdrawn